Reports Q2 revenue $60.7M, consensus $58.91M. “I am extremely pleased that KIMMTRAK is reaching more patients, with approvals now in over 35 countries, leading to another excellent quarter,” said Bahija Jallal, Chief Executive Officer of Immunocore. “I am also excited by the progress of our pipeline, as we announce the first Phase 3 trial with our PRAME-targeted ImmTAC, in first-line cutaneous melanoma.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IMCR:
- Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update
- Immunocore to report second quarter 2023 financial results and host call on August 10, 2023
- Immunocore initiated with a Hold at Canaccord on ‘modest’ near-term growth
- Immunocore initiated with a Hold at Canaccord
- Immunocore management to meet with Mizuho